Molecular basis and clinical application of biological markers of bone turnover

Endocrine Reviews

Volumn 17, Issue 4, 1996, Pages 333-368

  Calvo, Mona S ^a   Eyre, David R ^b,d   Gundberg, Caren M ^c,e  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Ostex International Inc   (United States)

^e BioMedical Technologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; ALKALINE PHOSPHATASE; ANDROGEN; BIOCHEMICAL MARKER; COLLAGEN TYPE 1; ESTROGEN; HYDROXYPROLINE; METHYLTESTOSTERONE; OSTEOCALCIN; PROCOLLAGEN; TARTARIC ACID; VITAMIN K GROUP; WARFARIN;

ADULT; BONE ATROPHY; BONE DENSITY; BONE DISEASE; BONE METABOLISM; BONE METASTASIS; BONE TURNOVER; CHILD; CLINICAL ARTICLE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; HYPERPARATHYROIDISM; HYPERTHYROIDISM; HYPOPARATHYROIDISM; MALE; OSSIFICATION; OSTEOLYSIS; OSTEOMALACIA; OSTEOPOROSIS; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; REVIEW; VITAMIN K DEFICIENCY;

ALKALINE PHOSPHATASE; ANIMALS; BIOLOGICAL MARKERS; BONE REMODELING; BONE RESORPTION; HUMANS; OSTEOCALCIN; PROCOLLAGEN;

EID: 0029799613     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.17.4.333     Document Type: Review

References (431)

1. Termine JD 1993 Bone matrix proteins and the mineralization process. In: Favus MJ (ed) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Raven Press, New York, pp 21-25
2. Mundy GR 1993 Bone resorbing cells. In: Favus MJ (ed) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Raven Press, New York, 25-32
3. Baron R 1993 Anatomy and ultrastructure of bone. In: Favus MJ (ed) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Raven Press, New York, pp 3-9
4. Puzas JE 1993 The osteoblast. In: Favus MJ (ed) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Raven Press, New York, pp 15-21
5. Väänänen HK 1993 Mechanism of bone turnover. Ann Med 25: 353-359
6. Tanzer ML 1973 Cross-linking of collagen. Science 180:561-566
7. Robey PG, Fisher LW, Young MF, Termine JD 1988 The biochemistry of bone. In: Riggs BL, Melton III LJ (eds) Osteoporosis: Etiology, Diagnosis and Management. Raven Press, New York, pp 95-109
8. Fessler JH, Fessler LI 1978 Biosynthesis of procollagen. Annu Rev Biochem 47:129-162
9. Goldberg B, Sherr CJ 1973 Secretion and extracellular processing of procollagen by cultured human fibroblasts. Proc Natl Acad Sci USA 70:361-365
10. Eyre DR 1984 Cross-linking in collagen and elastin. Annu Rev Biochem 53:717-748
11. Nordin BEC 1978 Diagnostic procedures in disorders of calcium metabolism. Clin Endocrinol (Oxf) 8:55-67
12. Kleerekoper M, Nelson DA, Peterson EL, Flynn MJ, Pawluszka AS, Jacobsen G, Wilson P 1994 Reference data for bone mass, calciotropic hormones, and biochemical markers of bone remodeling in older (55-75) postmenopausal white and black women. J Bone Miner Res 9:1267-1276
13. Prockop DJ, Kivirikko KI 1967 Relationship of hydroxyproline excretion in urine to collagen metabolism. Ann Intern Med 66: 1243-1266
14. Smith R 1980 Collagen and disorders of the bone. Clin Sci 59:215-223
15. Prockop DJ, Kivirikko KI 1984 Heritable diseases of collagen. N Engl J Med 311:376-386
16. Prockop DJ 1964 Isotopic studies on collagen degradation and the urine excretion of hydroxyproline. J Clin Invest 43:453-460
17. Lindstedt S, Prockop DJ 1961 Isotopic studies on urinary hydroxyproline as evidence for rapidly catabolized forms of collagen in the young rat. J Biol Chem 236:1399-1403
18. Haddad JG, Couranz S, Avioli LV 1970 Nondialyzable urinary hydroxyproline as an index of bone collagen formation. J Clin Endocrinol Metab 30:282-287
19. Prockop DJ, Kivirikko KI, Tuderman L, Guzman NA 1979 The biosynthesis of collagen and its disorders (first of two parts). N Engl J Med 301:13-23
20. Krane SM, Muñoz AJ, Harris Jr ED 1970 Urinary polypeptides related to collagen synthesis. J Clin Invest 49:716-729
21. Meilman E, Urivetzky MM, Rapoport CM 1963 Urinary hydroxyproline peptides. J Clin Invest 42:40-50
22. Reid KBM, Lowe DM, Porter RR 1972 Isolation and characterization of C1q, a subcomponent of the first component of complement, from human and rabbit sera. Biochem J 130:749-763
23. Reid KBM 1974 A collagen-like amino acid sequence in a polypeptide chain of human C1q (a subcomponent of the first component of complement). Biochem J 141:189-203
24. Prockop DJ, Sjoerdsma A 1961 Significance of urinary hydroxyproline in man. J Clin Invest 40:843-849
25. Gasser AB, Wootton R, Beyeler S, Celada A, Depierre D 1980 Biological variation in free serum hydroxyproline concentration. Clin Chim Acta 106:39-43
26. Podenphant J, Riis BJ, Larsen N-E, Christiansen C 1986 Hydroxyproline/creatinine ratios as estimates of bone resorption in early postmenopausal women. Fasting and 24-h urine samples compared. Scand J Clin Lab Invest 46:459-463
27. Niell HB, Palmieri GM, Neely CL, McDonald MW 1981 Postabsorptive urinary hydroxyproline test in patients with metastatic bone disease from breast cancer. Arch Intern Med 141:1471-1473
28. Mautalen CA, Casco C 1970 Circadian rhythm of urinary total and free hydroxyproline excretion and its relation to creatinine excretion. J Lab Clin Med 75:11-18
29. Jasin HE, Fink CW, Wise W, Ziff M 1962 Relationship between urinary hydroxyproline and growth. J Clin Invest 41:1928-1935
30. Neuman RE, Logan MA 1950 The determination of hydroxyproline. J Biol Chem 184:299-306
31. Prockop DJ, Udenfriend S 1960 A specific method for the analysis of hydroxyproline in tissues and urine. Anal Biochem 1:228-239
32. Kivirikko KI, Laitinen O, Prockop DJ 1967 Modifications of a specific assay for hydroxyproline in urine. Anal Biochem 19:249-255
33. Grant RA 1964 Estimation of hydroxyproine by the autoanalyser. J Clin Pathol 17:685-686
34. Bergman I, Loxley R 1970 The determination of hydroxyproline in urine hydrolysates. Clin Chim Acta 27:347-349
35. Goverde BC, Veenkamp FJ 1972 Routine assay of total urinary hydroxyproline based on resin-catalysed hydrolysis. Clin Chim Acta 41:29-40
36. Verch RL, Wallach S, Peabody RA 1979 Automated analysis of hydroxyproline with elimination of non-specific reacting substances. Clin Chim Acta 96:125-130
37. Pødenphant J, Larsen N-E, Christiansen C 1984 An easy and reliable method for determination of urinary hydroxyproline. Clin Chim Acta 142:145-148
38. Dawson CD, Jewell S, Driskell WJ 1988 Liquid-chromatographic determination of total hydroxyproline. Clin Chem 34:1572-1574
39. Wilson PS, Kleerekoper M, Bone H, Parfitt AM 1990 Urinary total hydroxyproline measured by HPLC: comparison of spot and timed urine collections. Clin Chem 36:388-389
40. Buttery JE, Stuart S 1988 Cost-effective modification of the hypronosticon procedure for urinary hydroxyproline. Clin Chem 34:773
41. Hughes H, Hagen L, Sutton RAL 1986 Liquid-chromatographic determination of 4-hydroxyproline in urine. Clin Chem 32:1002-1004
42. Lauffenburger T, Olah AJ, Dambacher MA, Guncaga J, Lentner C, Haas HG 1977 Bone remodeling and calcium metabolism: a correlated histomorphometric, calcium kinetic, and biochemical study in patients with osteoporosis and Paget's disease. Metabolism 26:589-606
43. 47Ca-kinetics. J Clin Invest 76:2254-2258
44. Saleh AEC, Coenegrachi JM 1968 The influence of age and weight on the urinary excretion of hydroxyproline and calcium. Clin Chim Acta 21:445-452
45. Allison DJ, Walker A, Smith QT 1966 Urinary hydroxyproline creatinine ratio of normal humans at various ages. Clin Chim Acta 14:729-734
46. Wakefield Jr T, Disney GW, Mason RL, Beauchene RE 1980 Relationships among anthropometric indices of growth and creatinine and hydroxyproline excretion in preadolescent black and white girls. Growth 44:192-204
47. Hyldstrup L, McNair P, Jensen GF, Nielsen HR, Transbøl I 1984 Bone mass as referent for urinary hydroxyproline excretion: age and sex-related changes in 125 normals and in primary hyperparathyroidism. Calcif Tissue Int 36:639-644
48. Hodgkinson A, Thompson T 1982 Measurement of the fasting urinary hydroxyproline: creatinine ratio in normal adults and its variation with age and sex. J Clin Pathol 35:807-811
49. Hart W, Duursma SA, Visser WJ, Njio LK 1975 The hydroxyproline content of plasma of patients with impaired renal function. Clin Nephrol 4:104-108
50. Russell RGG, Beard DJ, Cameron EC, Douglas DL, Forrest ARW, Guilland-Cumming D, Paterson AD, Poser J, Preston CJ, Milford-Ward A, Woodhead S, Kanis JA 1981 Biochemical markers of bone turnover in Paget's disease. Metab Bone Dis Rel Res 3:255-262
51. Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C 1988 Bone turnover in postmenopausal osteoporosis. J Clin Invest 82:1268-1274
52. Horowitz M, Need AG, Nordin BEC 1984 Effect of calcium supplementation on urinary hydroxyproline in osteoporotic postmenopausal women. Am J Clin Nutr 39:857-859
53. Horowitz M, Need AG, Philcox JC, Nordin BEC 1985 The effect of calcium supplements on plasma alkaline phosphatase and urinary hydroxyproline in postmenopausal women. Horm Metab Res 17:311-312
54. Horowitz M, Need AG, Morris HA, Wishart JM, Nordin BEC 1988 Biochemical effects of calcium supplementation in postmenopausal osteoporosis. Eur J Clin Nutr 42:775-778
55. Horowitz M, Wishart JM, Goh D, Morris HA, Need AG, Nordin BEC 1994 Oral calcium suppresses biochemical markers of bone resorption in normal men. Am J Clin Nutr 60:965-968
56. Aloia JF, Cohn SH, Zanzi I, Abesamis C, Ellis K 1978 Hydroxyproline peptides and bone mass in postmenopausal and osteoporotic women. J Clin Endocrinol Metab 47:314-318
57. Eastell R, Robins SP, Colwell T, Assiri AMA, Riggs BL, Russell RGG 1993 Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporosis Int 3:255-260
58. Goulding A, Brendon G, Bland R 1989 Fasting urinary calcium/ creatinine and hydroxyproline/creatinine values in young women with amenorrhoea and in matched eumenorrhoeic controls. NZ Med J 102:629-630
59. Christiansen C, Riis BJ, Rodbro P 1987 Prediction of rapid bone loss in postmenopausal women. Lancet 1:1105-1107
60. Eastell R, Delmas PD, Hodgson SF, Eriksen EF, Mann KG, Riggs BL 1988 Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers. J Clin Endocrinol Metab 67:741-748
61. Kotowicz MA, Melton III LJ, Cedel SL, O'Fallon WM, Riggs BL 1990 Effect of age on variables relating to calcium and phosphorus metabolism in women. J Bone Miner Res 5:345-352
62. Hansen M 1994 Assessment of age and risk factors on bone density and bone turnover in healthy premenopausal women. Osteoporosis Int 4:123-128
63. Mazzuoli G, Minisola S, Valtorta C, Antonelli R, Tabolli S, Bigi F 1985 Changes in mineral content and biochemical bone markers at the menopause. Isr J Med Sci 21:875-877
64. Stepán JJ, Pospichal J, Presl J, Pacovsky V 1987 Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women. Bone 8:279-284
65. Deacon AC, Hulme P, Hesp R, Green JR, Tellez M, Reeve J 1987 Estimation of whole body bone resorption rate: a comparison of urinary total hydroxyproline excretion with two radioisotopic tracer methods in osteoporosis. Clin Chim Acta 166:297-306
66. van der Wiel HE, Lips P, Nauta J, Netelenbos JC, Hazenberg GJ 1991 Biochemical parameters of bone turnover during ten days of bed rest and subsequent mobilization. Bone Miner 13:123-129
67. Overgaard K 1994 Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study. Calcif Tissue Int 55:82-86
68. Reginster J-Y, Jupsin I, Deroisy R, Biquet I, Franchimont N, Franchimont P 1995 Prevention of postmenopausal bone loss by rectal calcitonin. Calcif Tissue Int 56:539-542
69. Lyritis GP, Magiasis B, Tsakalakos N 1995 Prevention of bone loss in early nonsurgical and nonosteoporotic high turnover patients with salmon calcitonin: the role of biochemical bone markers in monitoring high turnover patients under calcitonin treatment. Calcif Tissue Int 56:38-41
70. Hodsman A, Fraher L, Ostbye T, Adachi J, Steer B 1993 An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J Clin Invest 91:1138-1148
71. Segrest JP, Cunningham LW 1970 Variations in human urinary o-hydroxylysyl glycoside levels and their relationship to collagen metabolism. J Clin Invest 49:1497-1509
72. Krane SM, Kantrowitz FG, Byrne M, Pinnell SR, Singer FR 1977 Urinary excretion of hydroxylysine and its glycosides as an index of collagen degradation. J Clin Invest 59:819-827
73. Pinnell SR, Fox R, Krane SM 1971 Human collagens: differences in glycosylated hydroxylysines in skin and bone. Biochim Biophys Acta 229:119-122
74. Grazioli V, Casari E, Murone M, Bonini PA 1993 High-performance liquid chromatographic method for measuring hydroxylysine glycosides and their ratio in urine as a possible marker of human bone collagen breakdown. J Chromatogr 615:59-66
75. Moro L, Noris-Suarez K, Michalsky M, Romanello M, de Bernard B 1993 The glycosides of hydroxylysine are final products of collagen degradation in humans. Biochim Biophys Acta 1156:288-290
76. Askenasi R 1975 Urinary excretion of free hydroxylysine, peptide-bound hydroxylysine and hydroxylysyl glycosides in physiological conditions. Clin Chim Acta 59:87-92
77. Moro L, Modricky C, Rovis L, de Bernard B 1988 Determination of galactosyl hydroxylysine in urine as a means for the identification of osteoporotic women. Bone Miner 3:271-276
78. Moro L, Mucelli RSP, Gazzarrini C, Modricky C, Marotti F, de Bernard B 1988 Urinary β-1-galactosyl-0-hydroxylysine (GH) as a marker of collagen turnover of bone. Calcif Tissue Int 42:87-90
79. Moro L, Modricky C, Stagni N, Vittur F, de Bernard B 1984 High-performance liquid chromatographic analysis of urinary hydroxylysyl glycosides as indicators of collagen turnover. Analyst 109:1621-1622
80. Yoshihara K, Mochidome N, Shida Y, Hayakaw Y, Nagata M 1993 Pre-column derivatization and its optimum conditions for quantitative determination of urinary hydroxylysine glycosides by high-performance liquid chromatography. Biol Pharm Bull 16:604-607
81. Moro L, Battista S, Modricky C, Rovis L, de Bernard B 1989 High-performance liquid chromatographic preparation of galactosyl-hydroxylysine, a specific bone collagen marker. J Chromatogr 490:285-292
82. Bettica P, Moro L, Robins SP, Taylor AK, Talbot J, Singer FR, Baylink DJ 1992 Bone-resorption markers galactosyl hydroxylysine, pyridinium crosslinks, and hydroxyproline compared. Clin Chem 38:2313-2318
83. Blumsohn A, Hannon R, Wrate R, Barton J, Al-Dehaimi A, Colwell A, Eastell R 1994 Biochemical markers of bone turnover in girls during puberty. Clin Endocrinol (Oxf) 40:663-670
84. Yoshihara K, Mochidome N, Hara T, Osada S, Takayama A, Nagata M 1994 Urinary excretion levels of hydroxylysine glycosides in osteoporotic patients. Biol Pharm Bull 17:836-839
85. Moro L, Gazzarrini C, Crivellari D, Galligioni E, Talamini R, de Bernard B 1993 Biochemical markers for detecting bone metastases in patients with breast cancer. Clin Chem 39:131-134
86. Bettica P, Taylor AK, Talbot J, Moro L, Talamini R, Baylink DJ 1996 Clincial performances of galactosyl hydroxylysine, pyridinoline, and deoxypyridinoline in postmenopausal osteoporosis. J Clin Endocrinol Metab 81:542-546
87. Eyre DR, Koob TJ, Van Ness KP 1984 Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography. Anal Biochem 137:380-388
88. Eyre DR, Dickson IR, Van Ness K 1988 Collagen cross-linking in human bone and articular cartilage. Biochem J 252:495-500
89. Eyre D 1987 Collagen cross-linking amino acids. Methods Enzymol 144:115-136
90. Seibel MJ, Robins SP, Bilezikian JP 1992 Urinary hydroxypyridinium cross-links of collagen: specific markers of bone resorption in metabolic bone disease. Trends Endocrinol Metab 3:263-270
91. Eyre DR 1995 The specificity of collagen cross-links as markers of bone and connective tissue degradation. Acta Orthop Scand 66 [Suppl 266]:166-170
92. Apone S, Fevold K, Lee M, Eyre D 1994 A rapid method for quantifying osteoclast activity in vitro. J Bone Miner Res 9:S178 (Abstract)
93. Robins SP 1995 Collagen crosslinks in metabolic bone disease. Acta Orthop Scand 66 [Suppl 266]:171-175
94. Colwell A, Russell RGG, Eastell R 1993 Factors affecting assay of urinary 3-hydroxypyridinium crosslinks of collagen as markers of bone resorption. Eur J Clin Invest 23:341-349
95. Black D, Duncan A, Robins SP 1988 Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Anal Biochem 169:197-203
96. Black D, Farquharson C, Robins SP 1989 Excretion of pyridinium cross-links of collagen in ovariectomized rats as urinary markers for increased bone resorption. Calcif Tissue Int 44:343-347
97. Seibel MJ, Duncan A, Robins SP 1989 Urinary hydroxy-pyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases. J Rheumatol 16:964-970
98. Beardsworth LJ, Eyre DR, Dickson IR 1990 Changes with age in the urinary excretion of lysyl- and hydroxylysylpyridinoline, two new markers of bone collagen turnover. J Bone Miner Res 5:671-676
99. Uebelhart D, Gineyts E, Chapuy M-C, Delmas PD 1990 Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 8:87-96
100. James I, Crowley C, Perrett D 1993 Assay of pyridinium crosslinks in serum using narrow-bore ion-paired reversed phase high-performance liquid chromatography. J Chromatogr 612:41-48
101. Gerrits MI, Thijssen JH, van Rijn HJ 1995 Determination of pyridinoline and deoxypyridinoline in urine, with special attention to retaining their stability. Clin Chem 41:571-574
102. Rosmalen FMA, Martens MFWC, van Hoek MJC, Wälchli R, Gamse R 1994 Light sensitivity of deoxypyridinoline: implications for the collection of urine. J Bone Miner Res 9:S334 (Abstract)
103. Seibel MJ, Gartenberg F, Silverberg SJ, Ratcliffe A, Robins SP, Bilezikian JP 1992 Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism. J Clin Endocrinol Metab 74:481-486
104. McLaren AM, Isdale AH, Whiting PH, Bird HA, Robins SP 1993 Physiological variations in the urinary excretion of pyridinium crosslinks of collagen. Br J Rheumatol 32:307-312
105. Uebelhart D, Schlemmer A, Johansen J, Gineyts E, Christiansen C, Delmas PD 1991 Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium crosslinks. J Clin Endocrinol Metab 72:367-373
106. Hassager C, Colwell A, Assiri AMA, Eastell R, Russell RGG, Christiansen C 1992 Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium cross-links: a longitudinal and cross-sectional study. Clin Endocrinol (Oxf) 37: 45-50
107. Body J, Delmas P 1992 Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia. J Clin Endocrinol Metab 74:471-475
108. Lipton A, Demers L, Daniloff Y, Curley E, Hamilton C, Harvey H, Witters L, Seaman J, Van der Glessen R, Seyedin S 1993 Increased urinary excretion of pyridinium cross-links in cancer patients. Clin Chem 39:614-618
109. Calabresi E, Lasagni L, Franceschelli L, Bartolini L, Serio M, Brandi ML 1994 Use of an internal standard to measure pyridinoline and deoxypyridinoline in urine. Clin Chem 40:336-337
110. Robins SP, Stead DA, Duncan A 1994 Precautions in using an internal standard to measure pyridinoline and deoxypyridinoline in urine. Clin Chem 40:2322-2323
111. Robins SP 1982 An enzyme-linked immunoassay for the collagen cross-link pyridinoline. Biochem J 207:617-620
112. Seibel MJ, Woitge H, Scheidt-Nave C, Leidig-Bruckner G, Duncan A, Nicol P, Ziegler R, Robins SP 1994 Urinary hydroxypyridinium cross-links of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study. J Bone Miner Res 9:1433-1440
113. Delmas PD, Gineyts E, Bertholin A, Garnero P, Marchand F 1993 Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease. J Bone Miner Res 8:643-648
114. Seyedin SM, Kung VT, Daniloff YN, Hesley RP, Gomez B, Nielsen LA, Rosen HN, Zuk RF 1993 Immunoassay for urinary pyridinoline: the new marker of bone resorption. J Bone Miner Res 8:635-642
115. Daniloff GY, Hesley RP, Ju J, Evans BJ, Seyedin SM 1993 An immunoassay for deoxypyridinoline. A highly specific marker of bone resorption. J Bone Miner Res 8:S357 (Abstract)
116. Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel M 1994 Direct enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 9:1643-1649
117. Martens MFWC, van Hoek MJC, Wälchli R, Gamse R, Rosmalen FMA 1994 The first radioimmunassay to measure deoxypyridinoline in urine and serum. J Bone Miner Res 9:S335 (Abstract)
118. Hanson DA, Weis MAE, Bollen A-M, Maslan SL, Singer FR, Eyre DR 1992 A specific immunoassay for monitoring human bone resorption: quantitiation of type I collagen cross-linked N-teleopeptides in urine. J Bone Miner Res 7:1251-1258
119. Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD 1995 Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 10:641-649
120. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C 1994 Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 40:2022-2025
121. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L 1993 Radioimmunassay for the pyridinoline cross-linked carboxy-terminal telopeptide of Type I collagen: a new serum marker of bone collagen degradation. Clin Chem 39:635-640
122. Hassager C, Risteli J, Risteli L, Jensen SB, Christiansen C 1992 Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women. J Bone Miner Res 7:1307-1311
123. Eriksen EF, Charles P, Melsen F, Mosekilde L, Risteli L, Risteli J 1993 Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res 8:127-132
124. Kawana K, Kushida K, Takahashi M, Ohishi T, Denda M, Yamazaki K, Inoue T 1994 The effect of menopause on biochemical markers and ultrasound densitometry in healthy females. Calcif Tissue Int 55:420-425
125. Ohishi T, Kushida K, Takahashi M, Kawana K, Yagi K, Kawakami K, Horiuchi K, Inoue T 1994 Urinary bone resorption markers in patients with metabolic bone disorders. Bone 15:15-20
126. Eastell R, Peel NFA, Hannon RA, Blumsohn A, Price A, Colwell A, Russell RGG 1993 The effect of age on bone collagen turnover as assessed by pyridinium crosslinks and procollagen I C-terminal peptide. Osteoporosis Int [Suppl 1]:S100-101
127. Schlemmer A, Hassager C, Jensen SB, Christiansen C 1992 Marked diurnal variation in urinary excretion of pyridinium crosslinks in premenopausal women. J Clin Endocrinol Metab 74:476-480
128. Blumsohn A, Herrington K, Hannon R, Shao P, Eyre DR, Eastell R 1994 The effect of calcium supplementation on the circadian rhythm of bone resorption. J Clin Endocrinol Metab 79:730-735
129. Eastell R, Calvo MS, Burritt MF, Offord KP, Russell RGG, Riggs BL 1992 Abnormalities in circadian patterns of bone resorption and renal calcium conservation in type I osteoporosis. J Clin Endocrinol Metab 74:487-494
130. Bollen A-M, Eyre D 1994 Bone resorption rates in children monitored by the urinary assay of collagen type I cross-linked peptides. Bone 15:31-34
131. Delmas PD, Schlemmer A, Gineyts E, Riis B, Christiansen C 1991 Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Min Res 6:639-644
132. Eastell R, Hampton L, Colwell A, Green JR, Assiri AMA, Hesp R, Russell RGG 1990 Urinary collagen crosslinks are highly correlated with radioisotropic measurements of bone resorption. In: Christiansen C, Overgaard K (eds) Osteoporosis. Osteopress ApS, Copenhagen, pp 469-470
133. Black D, Marabani M, Sturrock RD, Robins SP 1989 Urinary excretion of the hydroxypyridinium cross links of collagen in patients with rheumatoid arthritis. Ann Rheum Dis 48:641-644
134. McLaren AM, Hordon LD, Bird HA, Robins SP 1992 Urinary excretion of pyridinium crosslinks of collagen in patients with osteoporosis and the effects of bone fracture. Ann Rheum Dis 51:648-651
135. Seibel MJ, Cosman F, Shen V, Gordon S, Dempster DW, Ratcliffe A, Lindsay R 1993 Urinary hydroxypyridinium cross-links of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Miner Res 8:881-889
136. Harvey RD, McHardy KC, Reid IW, Paterson F, Bewsher PD, Duncan A, Robins SP 1991 Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridinium cross-links as specific urinary markers. J Clin Endocrinol Metab 72:1189-1194
137. Ohishi T, Takahashi M, Kushida K, Horiuchi K, Ishigaki S, Inoue T 1992 Quantitative analyses of urinary pyridinoline and deoxypyridinoline excretion in patients with hyperthyroidism. Endocr Res 18:281-290
138. Pecherstorfer M, Zimmer-Roth I, Schilling T, Woitge HW, Schmidt H, Baumgartner G, Thiebaud D, Ludwig H, Seibel MJ 1995 The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab 80: 97-103
139. Abbiati G, Arrigoni M, Frignani S, Longoni A, Bartucci F, Castiglioni C 1994 Effect of salmon calcitonin on deoxypyridinoline (Dpyr) urinary excretion in healthy volunteers. Calcif Tissue Int 55:346-348
140. Kollerup G, Hermann A, Brixen K, Lindblad B, Mosekilde L, Sørensen O 1994 Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis. Calcif Tissue Int 54:12-15
141. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700
142. Lieuw-A-Fa M, Sierra RI, Specker BL 1995 Carboxy-terminal propeptide of human type I collagen and pyridinium cross-links as markers of bone growth in infants 1 to 18 months of age. J Bone Miner Res 10:849-853
143. Alvarez L, Guañabens N, Peris P, Monegal A, Bedini JL, Deulofeu R, Martinez de Osaba MJ, Muñoz-Gomez J, Rivera-Fillat F, Ballesta AM 1995 Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's Disease. J Bone Miner Res 10:458-465
144. Rosen HN, Dresener-Pollak R, Moses AC, Rosenblatt M, Zeind AJ, Clemens JD, Greenspan SL 1994 Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue Int 54:26-29
145. Blumsohn A, Naylor KE, Assiri AMA, Eastell R 1995 Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease. Clin Chem 41:1592-1598
146. Prestwood KM, Pilbeam CC, Burleson JA, Woodiel FN, Delmas PD, Deftos LJ, Raisz LG 1994 The short term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab 79:366-371
147. Garnero P, Vassy V, Bertholin A, Riou J, Delmas P 1994 Markers of bone turnover in hyperthyroidism and the effects of treatment. J Clin Endocrinol Metab 78:955-959
148. Ureña P, Ferreira A, Kung VT, Morieux C, Simon P, Ang KS, Souberbielle JC, Segre GV, Drüeke TB, de Vernejoul MC 1995 Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. J Bone Miner Res 10: 932-939
149. Ezzat S, Melmed S, Endres D, Eyre DR, Singer FR 1993 Biochemical assessment of bone formation and resorption in acromegaly. J Clin Endocrinol Metab 76:1452-1457
150. Gertz BJ, Shao P, Hanson DA, Quan H, Harris ST, Genant HK, Chesnut III CH, Eyre DR 1994 Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res 9:135-142
151. Brenner RE, Vetter U, Bollen A-M, Mörike M, Eyre DR 1994 Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta. J Bone Miner Res 9:933-937
152. Key Jr LL, Rodriguiz RM, Willi SM, Wright NM, Hatcher HC, Eyre DR, Cure JK, Griffin PP, Ries WL 1995 Long-term treatment of osteopetrosis with recombinant human interferon gamma. N Engl J Med 332:1594-1599
153. McClung MR, Tou CKP, Goldstein NH, Picot C 1995 Tiludronate therapy for Paget's disease of bone. Bone 17:493S-496S
154. Sowers M, Eyre D, Hollis BW, Randolph JF, Shapiro B, Jannausch ML, Crutchfield M 1995 Biochemical markers of bone turnover in lactating and nonlactating postpartum women. J Clin Endocrinol Metab 80:2210-2216
155. Garnero P, Gineytis E, Riou JP, Delmas PD 1994 Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 79:780-785
156. Ebeling PR, Atley LM, Guthrie JR, Burger HG, Dennerstein L, Hopper JL, Wark JD 1996 Bone turnover markers and bone density across the menopausal transition. J Clin Endocrinol Metab, in press
157. Demers LM, Costa L, Chinchilli VM, Gaydos L, Curley E, Lipton A 1995 Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 41:1489-1494
158. Sairanen S, Tähtelä R, Laitinen K, Karonen SL, Välimäki MJ 1994 Nocturnal rise in markers of bone resorption is not abolished by bedtime calcium or calcitonin. Calcif Tissue Int 55:349-352
159. Hassager C, Risteli J, Risteli L, Christiansen C 1994 Effect of the menopause and hormone replacement therapy on the carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen. Osteoporosis Int 4:349-352
160. Hassager C, Jensen L, Pødenphant J, Thomsen K, Christiansen C 1994 The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy. Calcif Tissue Int 54:30-33
161. Brahm H, Ljunggren Ö, Larsson K, Lindh E, Ljunghall S 1994 Effects of infusion of parathyroid hormone and primary hyperparathyroidism on formation and breakdown of type I collagen. Calcif Tissue Int 55:412-416
162. Minkin C 1982 Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 34: 285-290
163. Ward KM, Cockayne S 1993 Enzymology. In: Anderson SC, Cockayne S (eds) Clinical Chemistry Concepts and Applications. WB Saunders Co, Philadelphia, pp 238-279
164. Kraenzlin ME, Taylor AK, Baylink DJ 1989 Biochemical markers for bone formation and bone resorption. In: Lindh E, Thorell JI (eds) Clinical Impact of Bone and Connective Tissue Markers. Academic Press, New York, pp 289-303
165. Price CP, Kirwan A, Vader C 1995 Tartrate-resistant acid phosphatase as a marker of bone resorption. Clin Chem 41:641-643
166. Allen SH, Nuttleman PR, Ketcham CM, Roberts RM 1989 Purification and characterization of human bone tartrate-resistant acid phosphatase. J Bone Miner Res 4:47-55
167. Yam LT 1974 Clinical significance of the human acid phosphatases. Am J Med 56:604-617
168. Lau K-HW, Onishi T, Wergedal JE, Singer FR, Baylink DJ 1987 Characterization and assay of tartrate-resistant acid phosphatase activity in serum: potential use to assess bone resorption. Clin Chem 33:458-462
169. Whitaker KB, Cox TM, Moss DW 1989 An immunoassay of human band 5 ("tartrate-resistant") acid phosphatase that involves the use of anti-porcine uteroferrin antibodies. Clin Chem 35:86-89
170. Lam K-W, Lee P, Li C-Y, Yam LT 1980 Immunological and biochemical evidence for identity of tartrate-resistant isoenzymes of acid phosphatases from human serum and tissues. Clin Chem 26:420-422
171. Lam WK-W, Lai LC, Yam LT 1978 Tartrate-resistant (band 5) acid phosphatase activity measured by electrophoresis on acrylamide gel. Clin Chem 24:309-312
172. Schiele F, Artur Y, Floc'h AY, Siest G 1988 Total, tartrate-resistant, and tartrate-inhibited acid phosphotases in serum: biological variations and reference limits. Clin Chem 34:685-690
173. Cheung CK, Panesar NS, Haines C, Masarei J, Swaminathan R 1995 Immunoassay of a tartrate-resistant acid phosphatase in serum. Clin Chem 41:679-686
174. Lam K-W, Siemens M, Sun T, Li C-Y, Yam LT 1982 Enzyme immunoassay for tartrate-resistant acid phosphatase. Clin Chem 28:467-470
175. Kraenzlin ME, Lau K-HW, Liang L, Freeman TK, Singer FR, Stepan J, Baylink DJ 1990 Development of an immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase. J Clin Endocrinol Metab 71:442-451
176. Echetebu ZO, Cox TM, Moss DW 1987 Antibodies to porcine uteroferrin used in measurement of human tartrate-resistant acid phosphatase. Clin Chem 33:1832-1836
177. Malluche HH, Juvin R, Allen SH, Faugere MC 1991 Serum tartrate-resistant acid phosphatase reflects osteoclastic resorption better than PTH in dialyzed patients. J Am Soc Nephrol 2:337 (Abstract)
178. Juvin R, Allen SH, Faugere MC, Malluche HH 1991 Serum tartrate-resistant acid phosphatase reflects histomorphometric parameters of osteoclasts in dialyzed patients. J Bone Miner Res 6:S152 (Abstract)
179. Stepán JJ, Silinková-Málková E, Havránek T, Formánková J, Zichová M, Lachmanová J, Jodl J, Stiaková M, Broulík P, Pacovsky V
180. Sarnecchia L, Minisola S, Pacitti M, Carnevale V, Romagnoli E, Rosso R, Mazzuoli G 1991 Clinical usefulness of serum tartrate-resistant acid phosphatase activity determination to evaluate bone turnover. Scand J Clin Invest 51:517-524
181. de la Piedra C, Torres R, Rapado A, Cureil MD, Castro N 1989 Serum tartrate-resistant acid phosphatase and bone mineral content in postmenopausal osteoporosis. Calcif Tissue Int 45:58-60
182. Stepán J, Tesarová A, Havránek T, Jodl J, Formánková J, Pacovsky V 1985 Age and sex dependency of the biochemical indices of bone remodeling. Clin Chim Acta 151:273-283
183. Lueken SA, Arnaud SB, Taylor AK, Baylink DJ 1993 Changes in markers of bone formation and resorption in a bed rest model of weightlessness. J Bone Miner Res 8:1433-1438
184. Chamberlain P, Compston J, Cox TM, Hayman AR, Imrie RC, Reynolds K, Holmes SD 1995 Generation and characterization of monoclonal antibodies to human type-5 tartrate-resistant acid phosphatase: development of a specific immunoassay of the isoenzyme in serum. Clin Chem 41:1495-1499
185. Rico H, Villa LF 1993 Serum tartrate-resistant acid phosphatase (TRAP) as a biochemical marker of bone remodeling. Calcif Tissue Int 52:149-150
186. Coleman JE 1992 Structure and mechanism of alkaline phosphatase. Annu Rev Biophys Biomol Struct 21:441-483
187. Crofton PM 1982 Biochemistry of alkaline phosphatase isoenzymes. CRC Crit Rev Clin Lab Sci 16:161-194
188. Harris H 1989 The human alkaline phosphatases: what we know and what we don't know. Clin Chim Acta 186:133-150
189. Meyer-Sabellek W 1988 Alkaline phosphatases. Laboratory and clinical implications. J Chromatogr 429:419-444
190. Van Hoof VO, De Broe ME 1994 Interpretation and clinical significance of alkaline phosphatase isoenzyme patterns. Crit Rev Clin Lab Sci 31:197-293
191. Moss DW 1992 Perspectives in alkaline phosphatase research. Clin Chem 38:2486-2492
192. Millan JL 1988 Oncodevelopmental expression and structure of alkaline phosphatase genes. Anticancer Res 8:995-1004
193. Swallow DM, Povey S, Parkar M, Andrews PW, Harris H, Pym B, Goodfellow P 1986 Mapping of the gene coding for the human liver/bone/kidney isozyme of alkaline phosphatase to chromosome 1. Ann Hum Genet 50:229-235
194. Griffin CA, Smith M, Henthorn PS, Harris H, Weiss MJ, Raducha M, Emanuel BS 1987 Human placental and intestinal alkaline phosphatase genes map to 2q34-q37. Am J Hum Genet 41:1025-34
195. Weiss MJ, Ray K, Henthorn PS, Lamb B, Kadesch T, Harris H 1988 Structure of the human liver/bone/kidney alkaline phosphatase gene. J Biol Chem 263:12002-12010
196. Low MG, Saltiel AR 1988 Structural and functional roles of glycosyl-phosphatidylinositol in membranes. Science 239:268-275
197. Stinson RA, Hamilton BA 1994 Human liver plasma membranes contain an enzyme activity that removes membrane anchor from alkaline phosphatase and converts it to a plasma-like form. Clin Biochem 27:49-55
198. Low MG, Huang KS 1991 Factors affecting the ability of glycosylphosphatidylinositol-specific phospholipase D to degrade the membrane anchors of cell surface proteins. Biochem J 279:483-493
199. Li JY, Hollfelder K, Huang KS, Low MG 1994 Structural features of GPI-specific phospholipase D revealed by proteolytic fragmentation and Ca2+ binding studies. J Biol Chem 269:28963-28971
200. Wong YW, Low MG 1992 Phospholipase resistance of the glycosylphosphatidylinositol membrane anchor on human alkaline phosphatase. Clin Chem 38:2517-2525
201. Whyte MP 1994 Hypophosphatasia and the role of alkaline phosphatase in skeletal mineralization. Endocr Rev 15:439-461
202. Kiledjian M, Kadesch T 1991 Post-transcriptional regulation of the human liver/bone/kidney alkaline phosphatase gene. J Biol Chem 266:4207-4213
203. Weiss MJ, Cole DE, Ray K, Whyte MP, Lafferty MA, Mulivor RA, Harris H 1988 A missense mutation in the human liver/bone/ kidney alkaline phosphatase gene causing a lethal form of hypophosphatasia. Proc Natl Acad Sci USA 85:7666-7669
204. Henthorn PS, Whyte MP 1992 Missense mutations of the tissue-nonspecific alkaline phosphatase gene in hypophosphatasia. Clin Chem 38:2501-2505
205. Owen TA, Aronow M, Shalhoub V, Barone LM, Wilming L, Tassinari MS, Kennedy MB, Pockwinse S, Lian JB, Stein GS 1990 Progressive development of the rat osteoblast phenotype in vitro: reciprocal relationships in expression of genes associated with osteoblast proliferation and differentiation during formation of the bone extracellular matrix. J Cell Physiol 143:420-430
206. Harrison G, Shapiro I, Golub E 1995 The phosphatidylinositolglycolipid anchor on alkaline phosphatase facilitates mineralization initiation in vitro. J Bone Miner Res 10:568-573
207. Togari A, Arakawa S, Arai M, Matsumoto S 1993 Inhibition of in vitro mineralization in osteoblastic cells and in mouse tooth germ by phosphatidylinositol-specific phospholipase. Biochem Pharmacol 46:1668-1670
208. Stinson RA, Thacker JD, Lin C 1993 Expression and nature of the alkaline phosphatase gene in cultured osteosarcoma cells. Clin Chim Acta 221:105-114
209. Farley JR, Hall SL, Tanner MA, Wergedal JE 1994 Specific activity of skeletal alkaline phosphatase in human osteoblast-line cells regulated by phosphate, phosphate esters, and phosphate analogs and release of alkaline phosphatase activity inversely regulated by calcium. J Bone Miner Res 9:497-508
210. Farley JR, Kyeyune-Nyombi E, Tarbaux NM, Hall SL, Strong DD 1989 Alkaline phosphatase activity from human osteosarcoma cell line SaOS-2: an isoenzyme standard for quantifying skeletal alkaline phosphatase activity in serum. Clin Chem 35:223-229
211. Chamberlain B, Buttery J, Pannall P 1992 A simple electrophoretic method for separating elevated liver and bone alkaline phosphatase isoenzymes in plasma after neuraminidase treatment. Clin Chim Acta 208:219-224
212. Mazda T, Gyure WL 1988 Assay of alkaline phosphatase isoenzymes by a convenient precipitation and inhibition methodology. Chem Pharm Bull 36:1814-1818
213. Rosalki SB, Foo AY 1984 Two new methods for separating and quantifying bone and liver alkaline phosphatase isoenzymes in plasma. Clin Chem 30:1182-1186
214. Behr W, Barnert J 1986 Quantification of bone alkaline phosphatase in serum by precipitation with wheat-germ lectin: a simplified method and its clinical plausibility. Clin Chem 32:1960-1966
215. Rosalki SB 1994 Bone-origin alkaline phosphatase in plasma by wheat-germ lectin methods in bone disease. Clin Chim Acta 226: 143-150
216. Sorenson S 1988 Wheat-germ agglutinin method for measuring bone and liver isoenzymes of alkaline phosphatase assessed in post-menopausal osteoporosis. Clin Chem 34:1636-1640
217. Farley JR, Hall SL, Herring S, Libanati C, Wergedal JE 1993 Reference standards for quantification of skeletal alkaline phosphatase activity in serum by heat inactivation and lectin precipitation. Clin Chem 39:1878-1884
218. Burlina A, Plebani M, Secchiero S, Zaninotto M, Sciacovelli L 1991 Precipitation method for separating and quantifying bone and liver alkaline phosphatase isoenzymes. Clin Biochem 24:417-423
219. Rosalki SB, Ying Foo A, Burlina A, Prellwitz W, Steiber P, Neumeier D, Klein G, Poppe WA, Bodenmüller H 1993 Multicenter evaluation of Iso-ALP test kit for measurement of bone alkaline phosphatase activity in serum and plasma. Clin Chem 39:648-652
220. Crofton PM 1992 Wheat-germ lectin affinity electrophoresis for alkaline phosphatase isoforms in children: age-dependent reference ranges and changes in liver and bone disease. Clin Chem 38:663-670
221. Mattizaao M, Ramasamy I 1993 Wheat-germ lectin affinity electrophoresis of serum alkaline phosphatase with commercially available agarose gels. Clin Chem 39:1404-1407
222. Lawson GM, Katzmann JA, Kimlinger TK, O'Brien JF 1985 Isolation and preliminary characterization of a monoclonal antibody that interacts preferentially with the liver isoenzyme of human alkaline phosphatase. Clin Chem 31:381-385
223. Bruder S, Caplan A 1990 A monoclonal antibody against the surface of osteoblasts recognizes alkaline phosphatase isoenzymes in bone, liver, kidney, and intestine. Bone 11:133-139
224. Hill CS, Wolfert RL 1989 The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase. Clin Chim Acta 186: 315-320
225. Gomez Jr B, Ardakani S, Ju J, Jenkins D, Cerelli MJ, Daniloff GY, Kung VT 1995 Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 41: 1560-1566
226. Garnero P, Delmas PD 1993 Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 77: 1046-1053
227. England TE, Samsoondar J, Maw G 1994 Evaluation of the Hybritech Tandem-R Ostase immunoradiometric assay for skeletal alkaline phosphatase. Clin Biochem 27:187-189
228. Panigrahi K, Delmas PD, Singer F, Ryan W, Reiss O, Fisher R, Miller PD, Mizrahi I, Darte C, Kress BC, Christenson RH 1994 Characteristics of a two-site immunoradiometric assay for human skeletal alkaline phosphatase in serum. Clin Chem 40:822-828
229. Bouman AA, Scheffer PG, Ooms ME, Lips P, Netelenbos C 1995 Two bone alkaline phosphatase assays compared with osteocalcin as a marker of bone formation in healthy elderly women. Clin Chem 41:196-199
230. Farley JR, Hall SL, Ilacas D, Orcutt C, Miller BE, Hill CS, Baylink DJ 1994 Quantification of skeletal alkaline phosphatase in osteoporotic serum by wheat germ agglutinin precipitation, heat inactivation, and a two-site immunoradiometric assay. Clin Chem 40: 1749-1756
231. Domar U, Hirano K, Stigbrand T 1991 Serum levels of human alkaline phosphatase isoenzymes in relation to blood groups. Clin Chim Acta 203:305-314
232. Van Hoof VO, Hoylaerts MF, Geryl H, Van Mullem M, Lepoutre LG, De Broe ME 1990 Age and sex distribution of alkaline phosphatase isoenzymes by agarose electrophoresis. Clin Chem 36:875-878
233. Koyama I, Miura M, Matsuzaki H, Sakagishi Y, Komoda T 1985 Sugar-chain heterogeneity of human alkaline phosphatases: differences between normal and tumour-associated isozymes. Am J Dis Child 139:736-740
234. Langlois MR, Delanghe JR, Kaufman JM, De Buyzere ML, Van Hoecke MJ, Leroux-Roels GG 1994 Posttranslational heterogeneity of bone alkaline phosphatase in metabolic bone disease. Eur J Clin Chem Clin Biochem 32:675-680
235. Lehman FG 1980 Differentiation of human alkaline phosphatases by lectin binding affinity. Klin Wochenschr 58:947-951
236. Valenzuela GJ, Munson LA, Tarbaux NM, Farley JR 1987 Time-dependent changes in bone, placental, intestinal, and hepatic alkaline phosphatase activities in serum during human pregnancy. Clin Chem 33:1801-1806
237. Schiele F, Henny J, Hitz J, Peiticlerc C, Gueguen R, Siest G 1983 Total bone and liver alkaline phosphatases in plasma: biological variations and reference limits. Clin Chem 29:634-641
238. Tietz NW, Wekstein DR, Shuey DF, Brauer GA 1984 A two-year longitudinal reference range study for selected serum enzymes in a population more than 60 years of age. J Am Geriatr Soc 32:563-570
239. Nielsen H, Brixen K, Mosekilde L 1990 Diurnal rhythm in serum activity of wheat-germ lectin precipitable alkaline phosphatase: temporal relationships with the diurnal rhythm of serum osteocalcin. Scand J Clin Invest 50:851-856
240. McComb RB, Bowers Jr GN, Posen S (eds) 1979 Alkaline Phosphatase. Plenum Press, New York
241. Deftos LJ, Wolfert RL, Hill CS 1990 Bone alkaline phosphatase in Paget's disease. Horm Metab 23:559-561
242. Duda Jr RJ, O'Brien JF, Katzmann JA, Peterson JM, Mann KG, Riggs BL 1988 Concurrent assays of circulating bone gla-protein and bone alkaline phosphatase: effects of sex, age, and metabolic bone disease. J Clin Endocrinol Metab 66:951-957
243. Stepán JJ, Presl J, Broulik P, Pacovsky V 1987 Serum osteocalcin levels and bone alkaline phosphatase isoenzyme after oophorectomy and in primary hyperparathyroidism. J Clin Endocrinol Metab 64:1079-1082
244. Stepán JJ, Lachmanová J, Straková M, Pacovsky V 1987 Serum osteocalcin, bone alkaline phosphatase isoenzyme and plasma tartrate resistant acid phosphatase in patients on chronic maintenance hemodialysis. Bone Miner 3:177-183
245. Skillen AW, Pierides AM 1977 Serum alkaline phosphatase isoenzyme patterns in patients with chronic renal failure. Clin Chim Acta 80:339-346
246. Leung K, Fung K, Sher A, Li C, Lee K 1993 Plasma bone-specific alkaline phosphatase as an indicator of osteoblastic activity. J Bone Joint Surg 75-B:288-292
247. Burlina A, Rubin D, Secchiero S, Sciacovelli L, Zaninotto M, Plebani M 1994 Monitoring skeletal cancer metastases with the bone isoenzyme of tissue unspecific alkaline phosphatase. Clin Chim Acta 226:151-158
248. Posen S, Kleerekoper M, Cornish C 1973 Serum alkaline phosphatase in the diagnosis of metabolic bone disorders. In: Frame B, Parfitt AM, Duncan H (eds) Clinical Aspects of Metabolic Bone Disease. Excerpta Medica, Amsterdam, pp 74-91
249. Gallop PM, Lian JB, Hauschka PV 1980 Carboxylated calcium-binding proteins and vitamin K. N Engl J Med 302:1460-1466
250. Cairns JR, Price PA 1994 Direct demonstration that the vitamin K-dependent bone GIa protein is incompletely g-carboxylated in humans. J Bone Miner Res 9:1989-1997
251. Hauschka PV, Carr SA 1982 Calcium-dependent alpha-helical structure in osteocalcin. Biochemistry 21:2538-2547
252. Pan LC, Price PA 1985 The propeptide of rat bone g-carboxyglutamic acid protein shares homology with other vitamin K-dependent protein precursors. Proc Natl Acad Sci USA 82:6109-6113
253. Pan LC, Williamson MK, Price PA 1985 Sequence of the precursor to rat bone γ-carboxyglutamic acid protein that accumulates in warfarin-treated osteosarcoma cells. J Biol Chem 260:13398-13401
254. Gundberg CM, Clough ME 1992 The osteocalcin propeptide is not secreted in vivo or in vitro. J Bone Miner Res 7:73-80
255. Puchacz E, Lian JB, Stein GS, Wozney J, Huebner K, Croce C 1989 Chromosomal localization of the human osteocalcin gene. Endocrinology 124:2648-2650
256. Desbois C, Hogue DA, Karsenty G 1994 The mouse osteocalcin gene cluster contains three genes with two separate spatial and temporal patterns of expression. J Biol Chem 269:1183-1190
257. Rahman S, Oberdorf A, Montecino M, Tanhauser SM, Lian JB, Stein GS, Laipis PJ, Stein JL 1993 Multiple copies of the bone-specific osteocalcin gene in mouse and rat. Endocrinology 133: 3050-3053
258. Owen TA, Bortell R, Shalhoub V, Heinrichs A, Stein JL, Stein GS, Lian JB 1993 Postproliferative transcription of the rat osteocalcin gene is reflected by vitamin D-responsive developmental modifications in protein-DNA interactions at basal and enhancer promoter elements. Proc Natl Acad Sci USA 90:1503-1507
259. Ozono K, Liao J, Kerner S, Scott R, Pike JW 1990 The vitamin D-responsive element in the human osteocalcin gene. J Biol Chem 265:21881-21888
260. Stein GS, Lian JB, Stein JL, Van Wijnen AJ, Montecino M 1996 Transcriptional control of osteoblast growth and development. Physiol Rev 76:593-629
261. Hauschka PV, Lian JB, Cole DE, Gundberg CM 1989 Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 69:990-1047
262. Boivin G, Morel G, Lian JB, Anthoine-Terrier C, Dubois PM, Meunier PJ 1990 Localization of endogenous osteocalcin in neonatal rat bone and its absence in articular cartilage: effect of warfarin treatment. Virchows Arch [A] 417:505-512
263. Hauschka PV, Reid ML 1978 Timed appearance of a calcium-binding protein containing g-carboxyglutamic acid in developing chick bone. Dev Biol 65:426-434
264. Lian JB, Roufosse AH, Reit B, Glimcher MJ 1982 Concentrations of osteocalcin and phosphoprotein as a function of mineral content and age in cortical bone. Calcif Tissue Int 34:S82-S87
265. Ingram RT, Park Y-K, Clarke BL, Fitzpatrick LA 1994 Age- and gender-related changes in the distribution of osteocalcin in the extracellular matrix of normal male and female bone. J Clin Invest 93:989-997
266. Harris S, Enger R, Riggs B, Spelsberg T 1995 Development and characterization of a conditionally immortalized human fetal osteoblastic cell line. J Bone Miner Res 10:178-186
267. Pockwinse SM, Lawrence JB, Singer RH, Stein JL, Lian JB, Stein GS 1993 Gene expression at single cell resolution associated with development of the bone cell phenotype: ultrastructural and in situ hybridization analysis. Bone 14:347-352
268. Gerstenfeld LC, Chipman SD, Glowacki J, Lian JB 1987 Expression of differentiated function by mineralizing cultures of chicken osteoblasts. Dev Biol 122:49-60
269. Gerstenfeld L, Lian J, Gotoh Y, Lee D, Landis W, McKee M, Nanci A, Glimcher M 1989 Use of cultured embryonic chicken osteoblasts as a model of cellular differentiation and bone mineralization. Connect Tissue Res 21:215-225
270. Zhou H, Choong P, McCarthy R, Chou S, Martin T, Ng K 1994 In situ hybridization to show sequential expression of osteoblast gene markers during bone formation in vivo. J Bone Miner Res 9:1489-1500
271. Stein GS, Lian JB, Owen TA 1990 Relationship of cell growth to the regulation of tissue-specific gene expression during osteoblast differentiation. FASEB J 4:3111-3123
272. Chenu C, Colucci S, Grano M, Zigrino P, Barattolo R, Zambonin G, Baldini N, Vergnaud P, Delmas P, Zallone A 1994 Osteocalcin induces chemotaxis, secretion of matrix proteins and calcium-mediated intracellular signaling in human osteoclast-like cells. J Cell Biol 127:1149-1158
273. Glowacki J, Rey C, Cox K, Lian J 1989 Effects of bone matrix components on osteoclast differentiation. Connect Tissue Res 20: 121-129
274. Lian JB, Tassinari M, Glowacki J 1984 Resorption of implanted bone prepared from normal and warfarin-treated rats. J Clin Invest 73:1223-1226
275. Serre CM, Price P, Delmas PD 1995 Degradation of subcutaneous implants of bone particles from normal and warfarin-treated rats. J Bone Miner Res 10:1158-1167
276. Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, Smith E, Bonadio J, Goldstein S, Gundberg C, Bradley A, Karsenty G 1996 Osteocalcin inhibits bone formation in vivo by limiting osteoblast function. Nature, in press
277. Price PA, Williamson MK, Lothringer JW 1981 Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem 256:12760-12766
278. Brown J, Malaval L, Chapuy M, Delmas P, Edouard C, Meunier P 1984 Serum bone GLA-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet 19:1091-1093
279. Brown JP, Delmas PD, Arlot M, Meunier PJ 1987 Active bone turnover of the cortico-endosteal envelope in postmenopausal osteoporosis. J Clin Endocrinol Metab 64:954-959
280. Charhon SA, Delmas PD, Malaval L, Chavassieux PM, Arlot M, Chapuy M-C, Meunier PJ 1986 Serum bone Gla-protein in renal osteodystrophy: comparison with bone histomorphometry. J Clin Endocrinol Metab 63:892-897
281. Marie PJ, Sabbagh A, de Vernejoul M-C, Lomri A 1989 Osteocalcin and deoxyribonucleic acid synthesis in vitro and histomorphometric indices of bone formation in postmenopausal osteoporosis. J Clin Endocrinol Metab 69:272-279
282. 47Ca-kinetics and dynamic histomorphometry. Metabolism 36:11118-11124
283. Van Der Eems KL, Brown RD, Gundberg CM 1988 Circulating levels of 1,25 dihydroxyvitamin D, alkaline phosphatase, hydroxyproline, and osteocalcin associated with antler growth in white-tailed deer. Acta Endocrinol (Copenh) 118:407-414
284. Demiaux B, Arlot M, Chapuy M-C, Meunier PJ, Delmas PD 1992 Serum osteocalcin is increased in patients with osteomalacia: correlations with biochemical and histomorphometric findings. J Clin Endocrinol Metab 74:1146-1151
285. Charles P, Hasling C, Risteli L, Risteli J, Mosekilde L, Eriksen E 1992 Assessment of bone formation by biochemical markers in metabolic bone disease: separation between osteoblastic activity at the cell and tissue level. Calcif Tissue Int 51:406-411
286. 3 circulating levels in bone disorders in rats. Endocrinology 120: 2123-2130
287. Gundberg CM, Hauschka PV, Lian JB, Gallop PM 1984 Osteocalcin: isolation, characterization and detection. In: Moldave K (eds) Methods in Enzymology. Academic Press, New York, pp 516-544
288. Price PA, Nishimoto SK 1980 Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma. Proc Natl Acad Sci USA 77:2234-2238
289. Poser JW, Esch FS, Ling NC, Price PA 1980 Isolation and sequence of the vitamin K-dependent protein from human bone. J Biol Chem 255:8685-8691
290. Melick R, Farrugia W, Quelch K 1985 Plasma osteocalcin in man. Aust NZ J Med 15:410-416
291. Price P, Parthemore J, Deftos L 1980 New biochemical marker for bone metabolism. J Clin Invest 66:878-883
292. Delmas PD, Christiansen C, Mann KG, Price PA 1990 Bone gla protein (osteocalcin) assay standardization report. J Bone Miner Res 5:5-10
293. Blumsohn A, Hannon RA, Eastell R 1995 Apparent instability of osteocalcin in serum as measured with different commercially available immunoassays. Clin Chem 41:318-320
294. Power MJ, Gosling JP, Fottrell PF 1989 Radioimmunoassay of osteocalcin with polyclonal and monoclonal antibodies. Clin Chem 35:1408-1415
295. Gundberg CM, Weinstein RS 1986 Multiple immunoreactive forms of osteocalcin in uremic serum. J Clin Invest 77:1762-1767
296. Farrugia W, Melick R 1986 Metabolism of osteocalcin. Calcif Tissue Int 39:234-238
297. Garnero P, Grimaux M, Seguin P, Delmas PD 1994 Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res 9:255-264
298. Taylor AK, Linkhart S, Mohan S, Christenson RA, Singer FR, Baylink DJ 1990 Multiple osteocalcin fragments in human urine and serum as detected by a midmolecule osteocalcin radioimmunoassay. J Clin Endocrinol Metab 70:467-472
299. Tracy RP, Andrianorivo A, Riggs BL, Mann KG 1990 Comparison of monoclonal and polyclonal antibody-based immunoassays for osteocalcin: a study of sources of variation in assay results. J Bone Miner Res 5:451-461
300. Baumgrass R, Felsenberg D, Price PA 1995 The cross-reactivities of cathepsin generated bone GLA protein-fragments in different immunoassays. J Bone Miner Res 10:S339 (Abstract)
301. Garnero P, Grimaux M, Demiaux B, Preaudat C, Seguin P, Delmas PD 1992 Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay. J Bone Miner Res 7:1389-1398
302. Jaouhari J, Schiele F, Dragacci S, Tarallo P, Siest J-P, Henny J, Siest G 1992 Avidin-biotin enzyme immunoassay of osteocalcin in serum or plasma. Clin Chem 38:1968-1974
303. Hosoda K, Eguchi H, Nakamoto T, Kubota T, Honda H, Jindai S, Hasegawa R, Kiyoki M, Yamaji T, Shiraki M 1992 Sandwich immunoassay for intact human osteocalcin. Clin Chem 38:2233-2238
304. Monaghan DA, Power MJ, Fottrell PF 1993 Sandwich enzyme immunoassay of osteocalcin in serum with use of an antibody against human osteocalcin. Clin Chem 39:942-947
305. Parviainen M, Kuronen I, Kokko H, Lakaniemi M, Savolainen K, Mononen I 1994 Two-site enzyme immunoassay for measuring intact human osteocalcin in serum. J Bone Miner Res 9:347-354
306. Kuronen I, Kokko H, Parviainen M 1993 Production of monoclonal and polyclonal antibodies against human osteocalcin sequences and development of a two-site ELISA for intact human osteocalcin. J Immunol Methods 163:223-240
307. Deftos LJ, Wolfert RL, Hill CS, Burton DW 1992 Two-site assays of bone Gla protein (osteocalcin) demonstrate immunochemical heterogeneity of the intact molecule. Clin Chem 38:2318-2321
308. Power MJ, O'Dwyer B, Breen E, Fottrell PF 1991 Osteocalcin concentrations in plasma prepared with different anticoagulants. Clin Chem 37:281-284
309. Thiede MA, Smock SL, Petersen DN, Grasser WA, Thompson DD, Nishimoto SK 1994 Presence of messenger ribonucleic acid encoding osteocalcin, a marker of bone turnover, in bone marrow megakaryocytes and peripheral blood platelets. Endocrinology 135:929-937
310. Rosenquist C, Quist P, Bjarnason N, Christiansen C 1995 Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem 41:1439-1445
311. Riggs BL, Tsai K-S, Mann KG 1986 Effect of acute increases in bone matrix degradation on circulating levels of bone-Gla protein. J Bone Miner Res 1:539-542
312. Cole DEC, Carpenter TO, Gundberg CM 1985 Serum osteocalcin concentrations in children with metabolic bone disease. J Pediatr 106:770-776
313. Delmas PD, Glorieux FH, Delvin EE, Salle BL, Melki I 1987 Perinatal serum bone gla-protein and vitamin D metabolites in preterm and fullterm neonates. J Clin Endocrinol Metab 65:588-591
314. Klein G, Wadlington E, Collins E, Catherwood B, Deftos L 1984 Calcitonin levels in sera of infants and children: relations to age and periods of bone growth. Calcif Tissue Int 36:635-638
315. Riis BJ, Krabbe S, Christiansen C, Catherwood BD, Deftos LJ 1985 Bone turnover in male puberty: a longitudinal study. Calcif Tissue Int 37:213-217
316. Cantatore F, Carrozzo M, Magli D, D'Amore M, Pipitone V 1988 Serum osteocalcin levels in normal humans of different sex and age. Panminerva Med 30:23-25
317. Catherwood B, Marcus R, Madvig P, Cheung A 1985 Determinants of bone gamma-carboxyglutamic acid-containing protein in plasma of healthy aging subjects. Bone 6:9-13
318. del Pino J, Martín-Gómez E, Martín-Rodríguez M, López-Sosa C, Cordero M, Lanchares JL, García-Talavera JR 1991 Influence of sex, age and menopause in serum osteocalcin (BGP) levels. Klin Wochenschr 69:1135-1138
319. Delmas PD, Stenner D, Wahner HW, Mann KG, Riggs BL 1983 Increase in serum bone g-carboxyglutamic acid protein with aging in women. J Clin Invest 71:1316-1321
320. Epstein S, McClintock R, Bryce G, Poser J, Johnston Jr CC, Hui S 1984 Differences in serum bone gla protein with age and sex. Lancet 11:307-310
321. Galli M, Caniggia M 1984 Osteocalcin in normal adult humans of different sex and age. Horm Metab Res 17:165-166
322. Johansen JS, Thomsen K, Christiansen C 1987 Plasma bone Gla protein concentrations in healthy adults. Dependence on sex, age, and glomerular filtration. Scand J Clin Lab Invest 47:345-350
323. Steinberg K, Rogers T 1987 Alkaline phosphatase isoenzymes and osteocalcin in serum of normal subjects. Ann Clin Lab Sci 17:241-250
324. Nilas L, Christiansen C 1987 Bone mass and its relationship to age and the menopause. J Clin Endocrinol Metab 65:697-702
325. Bell NH, Green A, Epstein S, Oexmann J, Shaw S, Shary J 1985 Evidence for alteration of the vitamin D endocrine system in blacks. J Clin Invest 76:470-473
326. Villa ML, Marcus R, Ramirez Delay R, Kelsey JL 1995 Factors contributing to skeletal health of postmenopausal Mexican-American women. J Bone Miner Res 10:1233-1242
327. Gundberg CM, Looker AC, Calvo MS 1995 Racial/ethnic differences in circulating osteocalcin. J Bone Miner Res 10:S300 (Abstract)
328. Farrugia W, Yates NA, Fortune CL, McDougall JG, Scoggins BA, Wark JD 1991 The effect of uninephrectomy on osteocalcin metabolism in sheep: a direct evaluation of renal osteocalcin clearance. J Endocrinol 130:213-221
329. 2D levels in renal disease. Kidney Int 24:104-109
330. Delmas PD, Wilson DM, Mann KG, Riggs BL 1983 Effect of renal function on plasma levels of bone Gla-protein. J Clin Endocrinol Metab 57:1028-1030
331. Friedman A, Heiliczer J, Gundberg C, Mak R, Boineau F, McEnery P, Chan J 1990 Serum osteocalcin concentrations in children with chronic renal insufficiency who are not undergoing dialysis. J Pediatr 116[Suppl]:S55-S59
332. Gundberg CM, Hanning RM, Liu A, Zlotkin SH, Balfe JW, Cole DE 1987 Clearance of osteocalcin by peritoneal dialysis in children with end-stage renal disease. Pediatr Res 21:296-300
333. Sebert JL, Ruiz JC, Fournier A, Fardellone P, Gueris J, Marie A, Moriniere PH, Codet MP, Renaud H 1987 Plasma bone Gla-protein: assessment of its clinical value as an index of bone formation in hemodialyzed patients. J Bone Miner Res 2:21-27
334. Epstein S, Traberg H, Raja R, Poser J 1985 Serum and dialysate osteocalcin levels in hemodialysis and peritoneal dialysis patients and after renal transplantation. J Clin Endocrinol Metab 60:1253-1256
335. Malluche HH, Faugere M-C, Fanti P, Price PA 1984 Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis. Kidney Int 26:869-874
336. 3 administration in a long-term follow-up. Kidney Int 28:783-790
337. Gundberg CM, Markowitz ME, Mizruchi M, Rosen JF 1985 Osteocalcin in human serum: a circadian rhythm. J Clin Endocrinol Metab 60:736-739
338. Nielsen HK, Brixen K, Kassem M, Charles P, Mosekilde L 1992 Inhibition of the morning cortisol peak abolishes the expected morning decrease in serum osteocalcin in normal males: evidence of a controlling effect of serum cortisol on the circadian rhythm in serum osteocalcin. J Clin Endocrinol Metab 74:1410-1414
339. Nielsen H, Brixen K, Kassem M, Christensen SE, Mosekilde L 1991 Diurnal rhythm in serum osteocalcin: relation to sleep, growth hormone, and PTH (1-84). Calcif Tissue Int 49:373-377
340. Nielsen HK 1994 Circadian and circatrigintan changes in osteoblastic activity assessed by serum osteocalcin. Dan Med Bull 41: 216-227
341. Rodin A, Duncan A, Quartero H, Pistofidis G, Mashiter G, Whitaker K, Crook D, Stevenson J, Chapman M, Fogelman I 1989 Serum concentrations of alkaline phosphatase isoenzymes and osteocalcin in normal pregnancy. J Clin Endocrinol Metab 68:1123-1127
342. Cole D, Gundberg CM, Stirk LJ, Atkinson SA, Hanley DA, Ayer LM, Baldwin LS 1987 Changing osteocalcin concentrations during pregnancy and lactation: implications for maternal mineral metabolism. J Clin Endocrinol Metab 65:290-294
343. Martinez ME, De Pedro C, Catalan P, Salinas M, Balaguer G, Ordas J 1985 Levels of osteocalcin in normal pregnancy [letter]. Am J Obstet Gynecol 153:708-709
344. Tarallo P, Henny J, Fournier B, Siest B 1990 Plasma osteocalcin: biological variations and reference limits. Scand J Clin Lab Invest 50:649-655
345. Lian JB, Gundberg CM 1988 Biochemical considerations and clinical applications. Clin Orthop 226:267-291
346. Power MJ, Fottrell PF 1991 Osteocalcin: diagnostic methods and clinical applications. Crit Rev Clin Lab Sci 28:287-335
347. Delmas PD, Demiaux B, Malaval L, Chapuy M, Meunier P 1986 Serum bone GLA-protein is not a sensitive marker of bone turnover in Paget's disease of bone. Calcif Tissue Int 38:60-61
348. Slovik RM, Gundberg CM, Neer RM, Lian JB 1984 Clinical evaluation of bone turnover by serum osteocalcin measurements. J Clin Endocrinol Metab 59:228-230
349. Price PA, Williamson MK 1981 Effects of warfarin on bone. J Biol Chem 256:12754-12758
350. Sokoll L, O'Brien ME, Camilo ME, Sadowski JA 1995 Undercarboxylated osteocalcin: development of a method to determine vitamin K status. Clin Chem 41:1121-1128
351. Caniggia A, Nuti R, Galli M, Lore F, Turchetti V, Righi GA 1986 Effect of a long-term treatment with 1,25-dihydroxyvitamin D3 on osteocalcin in postmenopausal osteoporosis. Calcif Tissue Int 38: 328-332
352. Delmas PD, Wahner HW, Mann KG, Riggs BL 1983 Assessment of bone turnover in postmenopausal osteoporosis by measurement of serum bone Gla-protein. J Lab Clin Med 102:470-476
353. Gundberg CM, Lian JB, Gallop PM, Steinberg JJ 1983 Urinary g-carboxyglutamic acid and serum osteocalcin as bone markers: studies in osteoporosis and Paget's disease. J Clin Endocrinol Metab 57:1221-1225
354. Ismail F, Epstein S, Pacifici R, Droke D, Thomas B, Avioli L 1986 Serum bone Gla protein and other markers of bone mineral metabolism in postmenopausal osteoporosis. Calcif Tissue Int 39:230-233
355. Pødenphant J, Christiansen C, Catherwood B, Deftos LJ 1985 Serum bone Gla protein and other biochemical estimates of bone turnover in early postmenopausal women during prophylactic treatment for osteoporosis. Acta Med Scand 218:329-333
356. Delmas PD, Stenner D, Heinz W, Wahner K, Mann G, Riggs L 1983 Increase in serum bone gamma-carboxyglutamic acid protein with aging in women. Implications for the mechanism of age-related bone loss. J Clin Invest 71:1316-1321
357. Yasumura S, Aloia JF, Gundberg CM, Yeh J, Vaswani AN, Yuen K, Monte AFL, Ellis KJ, Cohn SH 1987 Serum osteocalcin and total body calcium in normal pre-
358. Harris ST, Gertz BJ, Genant HK, Eyre DR, Survill TT, Ventura JN, DeBrock J, Ricerca E, Chesnut III CH 1993 The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 76:1399-1406
359. Duda Jr RJ, Kumar R, Nelson KI, Zinsmeister AR, Mann KG, Riggs BL 1987 1,25-Dihydroxyvitamin D stimulation test for osteoblast function in normal and osteoporotic postmenopausal women. J Clin Invest 79:1249-1253
360. 3 administration raises serum osteocalcin in patients with postmenopausal osteoporosis. J Clin Endocrinol Metab 60:615-617
361. Stock JL, Coderre JA, Mallette LE 1985 Effects of a short course of estrogen on mineral metabolism in postmenopausal women. J Clin Endocrinol Metab 61:595-600
362. Pak CY, Sakhaee K, Gallagher C, Parcel C, Peterson R, Zerwekh JE, Lemke M, Britton F, Hsu M-C, Adams B 1986 Attainment of therapeutic fluoride levels in serum without major side effects using a slow-release preparation of sodium fluoride in postmenopausal osteoporosis. J Bone Miner Res 1:563-571
363. Price PA, Kaneda Y 1987 Vitamin K counteracts the effect of warfarin in liver but not in bone. Thromb Res 46:121-131
364. Knapen MH, Hamulyák K, Vermeer C 1989 The effect of vitamin K supplementation on circulating osteocalcin (bone cell Gla protein) and urinary calcium excretion. Ann Intern Med 111:1001-1005
365. Hodges SJ, Pilkington MJ, Stamp TCB, Catterall A, Shearer MJ, Bitensky L, Chayen J 1991 Depressed levels of circulating menaquinones in patients with osteoporotic fractures of the spine and femoral neck. Bone 12:387-389
366. Szulc P, Chapuy M-C, Meunier P, Delmas P 1993 Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest 91:1769-1774
367. Ferland G, Sadowski JA, O'Brien ME 1993 Dietary induced subclinical vitamin K deficiency in normal human subjects. J Clin Invest 91:1761-1768
368. Sadowski JA, Hood SJ, Dallal GE, Garry PJ 1989 Phylloquinine in plasma from elderly and young adults: factors influencing its concentration. Am J Clin Nutr 50:100-108
369. Piro LD, Whyte MP, Murphy WA, Birge SJ 1982 Normal cortical bone mass in patients after long term coumadin therapy. J Clin Endocrinol Metab 54:470-473
370. Rosen NH, Maitland LA, Suttie JW, Manning WJ, Glynn RJ, Greenspan SL 1993 Vitamin K and maintenance of skeletal integrity in adults. Am J Med 94:62-68
371. Philip WJU, Martin JC, Richardson JM, Reid DM, Webster J, Douglas AS 1995 Decreased axial and peripheral bone density in patients taking long-term warfarin. Q J Med 88:635-640
372. Olsen BR, Guzman NA, Engel J, Condit C, Aase S 1977 Purification and characterization of a peptide from the carboxy-terminal region of chick tendon procollagen type I. Biochemistry 16:3030-3036
373. Smedsrod B, Melkko J, Risteli L, Risteli J 1990 Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J 271:345-350
374. Kivirikko KI, Myllyla R 1984 Biosynthesis of the collagens. In: Piez KA, Reddi AH (eds) Extracellular Matrix Biochemistry. Elsevier, New York, pp 83-119
375. Simon LS, Krane SM 1983 Procollagen extension peptides as mark ers of collagen synthesis. In: Frame B, Potts Jr JT (eds) Clinical Disorders of Bone and Mineral Metabolism. Excerpta Medica, Amsterdam, pp 108-111
376. Nimni ME 1983 Collagen: structure, function, metabolism in normal and fibrotic tissues. Semin Arthritis Rheum 13:1-86
377. Fisher LW, Robey PG, Tuross N, Otsuka AS, Tepen DA, Esch FS, Shimaski S, Termine JD 1987 The Mr 24,000 phosphoprotein from developing bone is the NH2-terminal propeptide of the alpha 1 chain of type I collagen. J Biol Chem 262:13457-13463
378. Melkko J, Niemi S, Risteli L, Risteli J 1990 Radioimmunassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 36:1328-1332
379. Simon L, Krane S, Wortan P, Krane I, Kovits K 1984 Serum levels of Type I and III procollagen fragments in Paget's disease of bone. J Clin Endocrinol Metab 58:110-120
380. Taubman MB, Goldberg B, Sherr C 1974 Radioimmunoassay for human procollagen. Science 186:1115-1117
381. Pedersen BJ, Bonde M 1994 Purification of human procollagen type I carboxyl-terminal propeptide cleaved as in vivo from procollagen and used to calibrate a radioimmunassay of the propeptide. Clin Chem 40:811-816
382. Ebeling PR, Peterson JM, Riggs BL 1992 Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J Bone Miner Res 7:1243-1250
383. Linkhart SG, Linkhart TA, Taylor AK, Wergedal JE, Bettica P, Baylink DJ 1993 Synthetic peptide-based immunoassay for amino-terminal propeptide of type I procollagen: application for evaluation of bone formation. Clin Chem 39:2254-2258
384. Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, Risteli J 1996 Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 42:947-954
385. Jensen FT, Olesen HP, Risteli J, Lorenzen I 1990 External thoracic duct-venous shunt in conscious pigs for long-term studies of connective tissue metabolites in lymph. Lab Anim Sci 40:620-624
386. Parfitt AM, Simon LS, Villanueva AR, Krane SM 1987 Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res 2:427-436
387. Hassager C, Jensen LT, Pødenphant J, Riis BJ, Christiansen C 1990 Collagen synthesis in postmenopausal women during therapy with anabolic steroid or female sex hormones. Metabolism 39:1167-1169
388. Pødenphant J, Riis BJ, Johansen JS, Leth A, Christiansen C 1988 Iliac crest biopsy in longitudinal therapeutic trials of osteoporosis. Bone Miner 5:77-87
389. Johansen JS, Hassager C, Pødenphant J, Riis BJ, Hartwell D, Thomsen K, Christiansen C 1989 Treatment of postmenopausal osteoporosis: is the anabolic steroid androlone decanoate a candidate? Bone Miner 6:77-86
390. Saggese G, Baroncelli I, Bertelloni S, Cinquanta L, DiNero G 1994 Twenty-four-hour osteocalcin, carboxyterminal propeptide of type I procollagen, and aminoterminal propeptide of type III procollagen rhythms in normal and growth-retarded children. Pediatr Res 35:409-415
391. Sgherzi M, Fabbri G, Bonati M, Maietta Latessa A, Segre A, De Vita D, De Leo V, Genazzani A, Petraglia F, Genazzani A 1994 Episodic changes of serum procollagen type I carboxy-terminal propeptide levels in fertile and postmenopausal women. Gynecol Obstet Invest 38:60-64
392. Minisola S, Romagnoli E, Scarnecchia L, Rosso R, Pacitti MT, Scarda A, Mazzuoli G 1994 Serum carboxy-terminal propeptide of human type I procollagen in patients with primary hyperparathyroidism: studies in basal conditions and after parathyroid surgery. Eur J Endocrinol 130:587-591
393. Legovini P, De Menis E, Da Rin G, Roiter I, Breda F, Artuso V, Di Virgilo R, Conte N 1994 Increased serum levels of carboxyterminal propeptide of type I collagen (PICP) in hyperthyroidism. Horm Metab Res 26:334-337
394. Li F, Iqbal J, Wassif W, Kaddam I, Moniz C 1994 Carboxyterminal propeptide of type I procollagen in osteomalacia. Calcif Tissue Int 55:90-93
395. Piovesan A, Berruti A, Osella G, Raucci CA, Torta M, Dogliotti L, Angeli A 1994 Serum levels of carboxyterminal propeptide of type I procollagen in cancer patients with osteoblastic and osteolytic bone metastasis. Int J Biol Markers 9:243-246
396. Charles P, Mosekilde L, Risteli L, Risteli J, Eriksen EF 1994 Assessment of bone remodeling using biochemical indicators of type I collagen synthesis and degradation: relation to calcium kinetics. Bone Miner 24:81-94
397. Minisola S 1995 Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta. J Bone Miner Res 10:335-336
398. Saggese G, Bertelloni S, Baroncelli G, Di Nero G 1992 Serum levels of carboxyterminal propeptide of type I procollagen in healthy children from 1rst year of life to adulthood and in metabolic bone diseases. Eur J Pediatr 151:764-768
399. Trivedi P, Risteli J, Hindmarsh PC, Brook CGD, Mowat AP 1991 Serum concentrations of the type I and type III procollagen propeptides as biochemical markers of growth velocity in healthy infants and children and in children with growth disorders. Pediatr Res 30:276-280
400. Hassager C, Fabbri-Mabelli G, Christiansen C 1993 The effect of the menopause and hormone replacement therapy on serum carboxy-terminal propeptide of type I collagen. Osteoporosis Int 3:50-52
401. Hassager C, Jensen L, Johansen J, Riis B, Melkko J, Pødenphant J, Risteli L, Christiansen C, Risteli J 1991 The carboxy-terminal propeptide of type I procollagen in serum as a marker of bone formation: the effect of nandrolone decanoate and female sex hormones. Metabolism 40:205-208
402. Tokita A, Kelly PJ, Nguyen TV, Qi J-C, Morrison NA, Risteli L, Risteli J, Sambrook PN, Eisman JA 1994 Genetic influences on Type I collagen synthesis and degradation: further evidence for genetic regulation of bone turnover. J Clin Endocrinol Metab 76: 1461-1466
403. Savolaienen ER, Goldberg B, Leo MA, Valez M, Lieber O 1984 Diagnostic value of serum procollagen peptide measurements on alcoholic liver disease. Alcohol Clin Exp Res 8:384-389
404. Lopez Gavilanes E, Gonzalez Parra E, de la Piedra C, Caramelo C, Rapado A 1994 Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure. Min Electrolyte Metab 20:259-264
405. Coen G, Mazzaferro S, Ballanti P, Bonucci E, Bondatti F, Manni M, Pasquali M, Perruzza I, Sardella D, Spurio A 1992 Procollagen type I C-terminal extension peptide in predialysis chronic renal failure. Am J Nephrol 12:246-251
406. Mazzaferro S, Pasquali M, Ballanti P, Bonucci E, Costantini S, Chicca S, De Meo S, Perruzza I, Sardella D, Taggi F, Coen G 1995 Diagnostic value of serum peptides of collagen synthesis and degradation in dialysis renal osteodystrophy. Nephrol Dial Transplant 10:52-58
407. Hamdy NA, Risteli J, Risteli L, Harris S, Beneton MN, Brown CB, Kanis JA 1994 Serum type I procollagen peptide: a non-invasive index of bone formation in patients on haemodialysis. Nephrol Dial Transplant 9:511-516
408. Eriksen EF, Brixen K, Charles P 1995 New markers of bone metabolism: clinical use in metabolic bone disease. Eur J Endocrinol 132:251-263
409. Delmas PD 1990 Biochemical markers of bone turnover for the clinical assessment of metabolic bone disease. Endocrinol Metab Clin North Am 19:1-18
410. Delmas PD 1993 Clinical use of biochemical markers of bone remodeling in osteoporosis. Bone 13:S17-S21
411. Demers LM, Kleerekoper M 1994 Recent advances in biochemical markers of bone turnover. Clin Chem 40:1994-1995
412. Epstein S 1988 Serum and urinary markers of bone remodeling: assessment of bone turnover. Endocr Rev 9:437-449
413. Falch JA 1994 Can biochemical markers tell us anything about rate of bone loss? Scand J Clin Lab Invest 54:40-41
414. Ljunghall S, Lindt E 1989 Assessment of bone turnover with biochemical markers. J Intern Med 225:219-220
415. Riis BJ 1991 Biochemical markers of bone turnover in diagnosis and assessment of therapy. Am J Med 91:64S-68S
416. Taylor AK, Lueken SA, Libanati C, Baylink DJ 1994 Biochemical markers of bone turnover for the clinical assessment of bone metabolism. Rheum Dis Clin North Am 20:589-607
417. Fledelius C, Riss BJ, Overgaard K, Christiansen C 1994 The diagnostic validity of urinary free pyridinolines to identify women at risk of osteoporosis. Calcif Tissue Int 54:381-384
418. Kassem M, Brixen K, Blum WF, Mosekilde L, Eriksen EF 1994 Normal osteoclastic and osteoblastic responses to exogenous growth hormone in patients with postmenopausal spinal osteoporosis. J Bone Miner Res 9:1365-1370
419. Whitehead HM, Boreham C, McIlrath EM, Sheridan B, Kennedy L, Atkinson AB, Hadden DR 1992 Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross-over study. Clin Endocrinol (Oxf) 36:45-52
420. Wollmann HA, Schonau E, Blum WF, Meyer F, Kruse K, Ranke MB 1995 Dose-dependent responses in insulin-like growth factors, insulin-like growth factor-binding protein-3 and parameters of bone metabolism to growth hormone therapy in young adults with growth hormone deficiency. Horm Res 43:249-256
421. Sanchez CP, Goodman WG, Brandli D, Goldenhersh M, Murray C, Carlton E, Hahn T, Salusky IB 1995 Skeletal response to recombinant human growth hormone (rhGH) in children treated with long-term corticosteroids. J Bone Miner Res 10:2-6
422. Garnero P, Sornay-Rendu E, Chapuy M-C, Delmas PD 1996 Increased bone turnover in late postmenopausal women is a major deteminant of osteoporosis. J Bone Miner Res 11:337-349
423. Raisz LG, Wiita B, Artis A, Bowen A, Schwartz S, Trahiotis M, Shoukri K, Smith J 1996 Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab 81:37-43
424. Hock JM, Fonseca J, Gunness-Hey M, Kemp BE, Martin TJ 1989 Comparison of the anabolic effects of synthetic parathyroid hormone related protein 1-34 and PTH 1-34 on bone in rats. Endocrinology 125:2022-2027
425. Liu C, Kalu DN 1990 Human parathyroid hormone (1-34) prevents bone loss and augments bone formation in sexually mature ovariectomized rats. J Bone Miner Res 5:973-982
426. Gundberg CM, Fawzi MI, Clough ME, Calvo MS 1995 A comparison of the effects of parathyroid hormone and parathyroid hormone-related protein on osteocalcin in the rat. J Bone Miner Res 10:903-909
427. Tam CS, Heersche JNM, Murray TM, Parsons JA 1982 Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action; differential effects of intermittent and continuous administration. Endocrinology 110:506-512
428. Masters PW, Jones RG, Purves DA, Cooper EH, Cooney JM 1994 Commercial assays for serum osteocalcin give clinically discordant results. Clin Chem 40:358-363
429. Christiansen C, Riis BJ, Rødbro P 1990 Screening procedure for women at risk for developing postmenopausal osteoporosis. Osteoporosis Int 1:35-40
430. Falch JA, Sandvik L, van Beresteijn ECH 1992 Development and evaluation of an index to predict early postmenopausal bone loss. Bone 13:337-341
431. Nielsen NM, von der Recke P, Hansen MA, Overgaard K, Christensen C 1994 Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers. Calcif Tissue Int 55:8-11